Stock Research for SLP

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

SLP Stock Chart & Research Data

The SLP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SLP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


SLP Due diligence Resources & Stock Charts

The SLP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View SLP Detailed Price Forecast - CNN Money CNN View SLP Detailed Summary - Google Finance
Yahoo View SLP Detailed Summary - Yahoo! Finance Zacks View SLP Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View SLP Trends & Analysis - Trade-Ideas Barrons View SLP Major Holders - Barrons
NASDAQ View SLP Call Transcripts - NASDAQ Seeking View SLP Breaking News & Analysis - Seeking Alpha
Spotlight View SLP Annual Report - CompanySpotlight.com OTC Report View SLP OTC Short Report - OTCShortReport.com
TradeKing View SLP Fundamentals - TradeKing Charts View SLP SEC Filings - Bar Chart
WSJ View Historical Prices for SLP - The WSJ Morningstar View Performance/Total Return for SLP - Morningstar
MarketWatch View the Analyst Estimates for SLP - MarketWatch CNBC View the Earnings History for SLP - CNBC
StockMarketWatch View the SLP Earnings - StockMarketWatch MacroAxis View SLP Buy or Sell Recommendations - MacroAxis
Bullish View the SLP Bullish Patterns - American Bulls Short Pains View SLP Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View SLP Stock Mentions - StockTwits PennyStocks View SLP Stock Mentions - PennyStockTweets
Twitter View SLP Stock Mentions - Twitter Invest Hub View SLP Investment Forum News - Investor Hub
Yahoo View SLP Stock Mentions - Yahoo! Message Board Seeking Alpha View SLP Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for SLP - SECform4.com Insider Cow View Insider Transactions for SLP - Insider Cow
CNBC View SLP Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for SLP - OTC Markets
Yahoo View Insider Transactions for SLP - Yahoo! Finance NASDAQ View Institutional Holdings for SLP - NASDAQ


Stock Charts

FinViz View SLP Stock Insight & Charts - FinViz.com StockCharts View SLP Investment Charts - StockCharts.com
BarChart View SLP Stock Overview & Charts - BarChart Trading View View SLP User Generated Charts - Trading View




Latest Financial News for SLP


DILIsym Awarded $1.5 Million Phase II NIH Grant
Posted on Thursday January 17, 2019

DILIsym Services, Inc., a Simulations Plus company (SLP) developing in silico modeling software, resources, and information for assisting the pharmaceutical industry to more efficiently develop safe and effective drug therapies, today announced it has been awarded $1.5 million from Phase II of its previously announced Fast-Track Small Business Innovation Research (SBIR) grant by the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK). The second phase of the grant funding will support DILIsym Services’ continued development, validation, and testing of its RENAsym software for predicting drug-induced kidney injury.


Edited Transcript of SLP earnings conference call or presentation 9-Jan-19 9:15pm GMT
Posted on Wednesday January 16, 2019

Q1 2019 Simulations Plus Inc Earnings Call


Simulations Plus Releases DDDPlus™ Version 6
Posted on Tuesday January 15, 2019

Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, and chemicals industries, today announced that it has released version 6 of its in vitro dissolution modeling software, DDDPlus™. John DiBella, president of the Lancaster division, added: “The DDDPlus client base has steadily increased over the years, with several regulatory agencies now using the program to assess dissolution method and product specification questions.


DILIsym Services Inc. Initiates Development of IPFsym™
Posted on Monday January 14, 2019

DILIsym Services Inc., a Simulations Plus company (SLP) and a leading provider of simulation and modeling software for pharmaceutical safety and efficacy, today announced that it is initiating development of IPFsym™, QSP (quantitative systems pharmacology) modeling software that will provide the ability to predict the efficacy of drugs being developed to treat idiopathic pulmonary fibrosis (IPF). The development of IPFsym is being sponsored by a large pharmaceutical company partner for $2.7 million, and it will be widely available via licensing and consulting for the broader pharmaceutical industry upon completion.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.